| 5.55 0.14 (2.59%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.52  |
1-year : | 8.42 |
| Resists | First : | 6.43 |
Second : | 7.21 |
| Pivot price | 5.76 |
|||
| Supports | First : | 5.19 | Second : | 4.31 |
| MAs | MA(5) : | 5.49 |
MA(20) : | 5.95 |
| MA(100) : | 7.87 |
MA(250) : | 10.07 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 19.2 |
D(3) : | 18.1 |
| RSI | RSI(14): 33.7 |
|||
| 52-week | High : | 15.38 | Low : | 5.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CERT ] has closed above bottom band by 33.3%. Bollinger Bands are 34.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.67 - 5.7 | 5.7 - 5.72 |
| Low: | 5.36 - 5.38 | 5.38 - 5.41 |
| Close: | 5.5 - 5.55 | 5.55 - 5.6 |
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Thu, 09 Apr 2026
Certara sets May 11 earnings release, webcast starts at 8:30 ET - Stock Titan
Thu, 09 Apr 2026
If You Invested $1,000 in Certara, Inc. (CERT) - Stock Titan
Wed, 08 Apr 2026
How The Certara (CERT) Story Is Evolving As Price Targets Reset And Growth Plans Lag - Yahoo Finance
Mon, 06 Apr 2026
Wasatch Advisors holds 5.27M Certara shares (NASDAQ: CERT) - Stock Titan
Sun, 05 Apr 2026
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates - MSN
Sun, 05 Apr 2026
CERT SEC Filings - Certara, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 159 (M) |
| Shares Float | 119 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 118.4 (%) |
| Shares Short | 23,790 (K) |
| Shares Short P.Month | 21,900 (K) |
| EPS | -0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.67 |
| Profit Margin | -0.4 % |
| Operating Margin | 2 % |
| Return on Assets (ttm) | 0.9 % |
| Return on Equity (ttm) | -0.2 % |
| Qtrly Rev. Growth | 3.2 % |
| Gross Profit (p.s.) | 1.61 |
| Sales Per Share | 2.63 |
| EBITDA (p.s.) | 0.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 96 (M) |
| Levered Free Cash Flow | 96 (M) |
| PE Ratio | -555.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.83 |
| Price to Sales | 2.1 |
| Price to Cash Flow | 9.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|